INVESTOR RELATIONS

KEY FIGURES

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions.

In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases.

Kedrion distributes its products in over 100 countries and is the world’s 5th top player in the field of plasma-derived products.

PRESS RELEASES

Kedrion SpA is hosting the 3Q 2023 earnings presentation.

Kedrion SpA is hosting the H1 2023 earnings presentation

Kedrion Results for the quarter ended March 31, 2023

FINANCIAL REPORTS

SUSTAINABILITY REPORTS

OTHER DOCUMENTS

CONTACT & EMAIL ALERTS

Subscribe to the service in order to receive our news


 

EN: Newsletter signup (Mailchimp)
Policy *
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For more information please contact: [email protected]